Skip to content
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • IL-2 Antibody
      • Anti-prolactin Antibody
      • XMetA Portfolio
      • Anti-PTH1R Antibody
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact
XOMA
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • IL-2 Antibody
      • Anti-prolactin Antibody
      • XMetA Portfolio
      • Anti-PTH1R Antibody
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Company & Partner News
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Financial Information
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Overview
    • Charts
    • Historical Data
    • IRS Form 8937
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents

Press Releases

XOMA’s Royalty Portfolio Grows with Addition of Three Royalty Assets

Apr 15, 2021 9:05am EDT

XOMA Announces Closing of Depositary Shares Offering and Exercise of Underwriters’ Option

Apr 12, 2021 7:30am EDT

XOMA Prices $35 Million Offering of Depositary Shares

Apr 06, 2021 7:01pm EDT

XOMA Announces Offering of Depositary Shares and Series B Cumulative Perpetual Preferred Stock

Apr 05, 2021 4:05pm EDT

Viracta and XOMA Announce Multi-License Milestone and Royalty Monetization Transaction

Mar 23, 2021 8:00am EDT

XOMA Announces Approval of First Preferred Stock Dividend

Mar 22, 2021 7:30am EDT

XOMA Reports Fourth Quarter and Full-Year 2020 Financial Results and Operating Highlights

Mar 10, 2021 7:30am EST

XOMA to Present at Upcoming Investor Conferences

Feb 23, 2021 4:05pm EST

XOMA to Present at H.C. Wainwright Virtual BioConnect 2021 and Biotech Showcase Digital Conferences

Jan 04, 2021 4:05pm EST

XOMA Announces Exercise of Green Shoe Option and Closes Preferred Stock Offering

Dec 21, 2020 5:00pm EST
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...39
Next
  • Email Alerts
  • RSS News Feed
  • Terms of Use

© 2021 XOMA Corporation.  All rights reserved.

All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

  • Follow us:
© 2021 XOMA • Powered by GeneratePress
Scroll back to top